0001235802-22-000096.txt : 20220817
0001235802-22-000096.hdr.sgml : 20220817
20220817163124
ACCESSION NUMBER: 0001235802-22-000096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220815
FILED AS OF DATE: 20220817
DATE AS OF CHANGE: 20220817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34951
FILM NUMBER: 221174546
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Orbimed ROF II LLC
CENTRAL INDEX KEY: 0001767936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34951
FILM NUMBER: 221174545
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVE., 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVE., 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc.
CENTRAL INDEX KEY: 0001453593
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205313323
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
BUSINESS PHONE: 406-388-0480
MAIL ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
FORMER COMPANY:
FORMER CONFORMED NAME: Bacterin International Holdings, Inc.
DATE OF NAME CHANGE: 20100615
FORMER COMPANY:
FORMER CONFORMED NAME: K KITZ INC
DATE OF NAME CHANGE: 20090108
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-08-15
0
0001453593
Xtant Medical Holdings, Inc.
XTNT
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK
NY
10022
1
0
1
0
0001767936
Orbimed ROF II LLC
601 LEXINGTON AVE., 54TH FLOOR
NEW YORK
NY
10022
1
0
1
0
Common Stock, $0.000001 par value
2022-08-15
4
J
0
215415
0
A
215415
I
See Footnotes
Common Stock, $0.000001 par value
2022-08-15
4
J
0
215415
0
A
215415
I
See Footnotes
This restricted stock unit award was granted to Michael Eggenberg ("Eggenberg"), a director of Xtant Medical Holdings, Inc. ("Xtant").
These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo ("Rizzo") remaining a director of Xtant through the vesting date.
See Exhibit 99.1.
This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of OrbiMed Advisors and ROF II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated certain representatives, including Rizzo and Eggenberg, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purposes.
This restricted stock unit award was granted to Rizzo, a director of Xtant.
/s/ Sven H. Borho, Member of OrbiMed Advisors LLC
2022-08-17
/s/ Sven H. Borho, Member of OrbiMed ROF II LLC
2022-08-17
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
2022-08-17
/s/ Carl L. Gordon, Member of OrbiMed ROF II LLC
2022-08-17
/s/ W. Carter Neild, Member of OrbiMed Advisors LLC
2022-08-17
/s/ W. Carter Neild, Member of OrbiMed ROF II LLC
2022-08-17
EX-99.1
2
exhibit99-1.txt
EXHIBIT 99.1
Upon vesting of the restricted stock unit award,
ownership of the shares underlying the restricted
stock unit award will be transferred to ROS Acquisition
Offshore LP (ROS Acquisition) and OrbiMed Royalty
Opportunities II, LP (ORO II). OrbiMed Advisors LLC
(OrbiMed Advisors), a registered investment advisor
under the Investment Advisors Act of 1940, as amended,
is the investment manager of ROS Acquisition. OrbiMed
Advisors is the managing member of OrbiMed ROF II LLC
(ROF II). ROF II is the general partner of ORO II.
OrbiMed Advisors may be deemed to have voting and
investment power with respect to the securities held
by ROS Acquisition. Each of OrbiMed Advisors and ROF II
may be deemed to have voting and investment power
with respect to the securities held by ORO II. OrbiMed
Advisors exercises its voting and investment power
through a management committee comprised of Carl L.
Gordon, Sven H. Borho, and W. Carter Neild, each of
disclaims beneficial ownership of the securities held
by ROS Acquisition and ORO II.